Financial Performance - The company's operating revenue for the third quarter was ¥747,334,981.28, a decrease of 14.27% compared to the same period last year[4] - The total profit for the quarter was ¥66,529,235.86, down 23.73% year-on-year[4] - The net profit attributable to shareholders was ¥65,111,696.75, reflecting a decline of 20.84% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses was ¥60,222,741.34, a decrease of 21.29% year-on-year[4] - The basic earnings per share for the quarter was ¥0.42, down 22.22% from the same period last year[5] - The weighted average return on equity decreased by 0.95 percentage points to 2.55%[5] - The company's net profit for the current period is CNY 288,603,789.34, a decrease of 11.09% compared to CNY 324,587,553.14 in the previous period[21] - Operating profit for the current period is CNY 304,365,030.94, down from CNY 352,785,660.72, reflecting a decline of 13.71%[21] - Total revenue from sales of goods and services for the current period is CNY 2,680,603,615.88, compared to CNY 3,120,748,668.08 in the previous period, indicating a decrease of 14.06%[24] - The basic and diluted earnings per share for the current period are both CNY 1.88, down from CNY 2.10 in the previous period[21] - The total comprehensive income attributable to the parent company's owners is CNY 285,737,321.93, a decrease from CNY 321,615,639.73 in the previous period[21] Assets and Liabilities - The company's total assets increased by 1.40% to ¥4,337,514,441.31 compared to the end of the previous year[5] - Current assets as of September 30, 2025, totaled CNY 2,587,186,889.28, slightly down from CNY 2,601,436,202.31 at the end of 2024[16] - Non-current assets increased to CNY 1,750,327,552.03 as of September 30, 2025, compared to CNY 1,676,193,203.82 at the end of 2024[17] - Total assets reached CNY 4,337,514,441.31, up from CNY 4,277,629,406.13 at the end of 2024[18] - Total liabilities decreased to CNY 1,737,330,864.95 from CNY 1,827,290,163.33 in the previous year[18] - Shareholders' equity increased to CNY 2,600,183,576.36 as of September 30, 2025, compared to CNY 2,450,339,242.80 at the end of 2024[18] - Cash and cash equivalents stood at CNY 175,220,075.80, up from CNY 163,173,887.90 at the end of 2024[16] - Accounts receivable rose to CNY 865,583,203.16 from CNY 807,667,332.99 in the previous year[16] - Inventory decreased to CNY 309,658,226.06 from CNY 354,311,612.84 at the end of 2024[16] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥139,050,345.38, an increase of 31.45%[10] - The net cash flow from operating activities is CNY 139,050,345.38, an increase from CNY 105,781,248.03 in the previous period[24] - The company reported a net cash outflow from financing activities of CNY -171,646,633.27, worsening from CNY -97,605,918.79 in the previous period[25] - The cash and cash equivalents at the end of the period stand at CNY 150,831,297.54, down from CNY 180,774,348.01 in the previous period[25] Segment Performance - The pharmaceutical manufacturing segment saw a revenue increase of 19.67% year-to-date, while the pharmaceutical commerce segment experienced a decline of 36.91%[8] - The net profit attributable to shareholders for the year-to-date period was ¥285,737,321.93, down 11.16% year-on-year, primarily due to reduced investment income from joint ventures and non-recurring gains and losses[8] Research and Development - Research and development expenses increased to CNY 78,318,937.23, up 29.66% from CNY 60,448,309.19 in the previous period[21]

智通财经APP讯，健民集团(600976.SH)披露2025年第三季度报告，公司前三季度实现营收25.52亿元， 同比下降11.43%;归属于上市公司股东的净利润2.86亿元，同比下降11.16%;扣非净利润2.56亿元，同比 下降5.58%;基本每股收益1.88元。 ...

前三季度公司营业收入同比下降11.43%，其中医药工业同比增长19.67%，主要是公司主导产品及新产 品收入增长所致；医药商业收入同比下降36.91%，主要是公司持续优化下属商业子公司业务结构，逐 步收缩了部分低毛低效的业务，导致医药商业板块业务收入有所下降。 格隆汇10月21日丨健民集团(600976.SH)公布，公司前三季度实现营业收入25.52亿元，同比下降 11.43%；归属于上市公司股东的净利润2.86亿元，同比下降11.16%；归属于上市公司股东的扣除非经常 性损益的净利润2.56亿元，同比下降5.58%；基本每股收益1.88元。 ...

健民集团公告，第三季度营收为7.47亿元，下降14.27%；净利润为6511.17万元，下降20.84%。前三季 度营收为25.52亿元，下降11.43%；净利润为2.86亿元，下降11.16%。 ...

Core Points - Jianmin Group's stock price increased by 2.06% on October 21, reaching 40.58 CNY per share, with a total market capitalization of 6.225 billion CNY [1] - The company has experienced a 0.49% decline in stock price year-to-date, with a 2.14% increase over the last five trading days [2] - Jianmin Group's main business involves the research, manufacturing, wholesale, and retail of pharmaceuticals, with 99.47% of revenue coming from product sales [2] Financial Performance - For the first half of 2025, Jianmin Group reported operating revenue of 1.805 billion CNY, a year-on-year decrease of 10.20%, and a net profit attributable to shareholders of 221 million CNY, down 7.83% year-on-year [2] - The company has distributed a total of 1.114 billion CNY in dividends since its A-share listing, with 476 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 29.30% to 17,000, while the average circulating shares per person decreased by 22.66% to 9,011 shares [2] - Major shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 203.04 million shares, and new entrant Rongtong Health Industry Flexible Allocation Mixed A/B [3]

Core Viewpoint - The company will hold an investor briefing on October 22, 2025, to discuss its Q3 2025 financial results and address common investor concerns [2][3][4]. Group 1: Meeting Details - The investor briefing is scheduled for October 22, 2025, from 16:00 to 17:00 [4]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an online text interaction format [4][5]. - Participants will include the company's chairman, independent directors, president, CFO, and board secretary [4]. Group 2: Participation Information - Investors can join the briefing online via the Shanghai Stock Exchange Roadshow Center [5]. - Questions can be submitted from October 15 to October 21, 2025, through the Roadshow Center's website or via the company's email [5]. - The company will respond to commonly asked questions during the briefing [3][5]. Group 3: Contact Information - Contact persons for inquiries are Cao Hong and Wang Miao, with a provided phone number [6]. - The company's email for investor questions is ir.jmjt@whjm.com [6]. Group 4: Additional Information - After the briefing, investors can access the meeting's details and main content through the Shanghai Stock Exchange Roadshow Center [7]. - The company expresses gratitude for investor support and encourages participation in the online briefing [7].

证券代码：600976 证券简称：健民集团 公告编号：2025-035 健民药业集团股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2025 年 10 月 22 日(星期三)下午 16:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 一、说明会类型 本次投资者说明会以网络文字互动形式召开，公司将针对 2025 年第三季度 的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允 许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 (一) 会议召开时间：2025 年 10 月 22 日(星期三)下午 16:00-17:00 (二) 会议召开地点：上海证券交易所上证路演中心 (三) 会议召开方式：上证路演中心网络文字互动 三、参加人员 公司董事长袁平东先生、独立董事郭云沛先生、 ...

截至发稿，健民集团市值为62亿元。 每经头条（nbdtoutiao）——天水麻辣烫、淄博烧烤、荣昌卤鹅⋯⋯"泼天流量"退去后，这些城市怎么 样了？ 每经AI快讯，健民集团（SH 600976，收盘价：40.29元）10月10日晚间发布关于对子公司银行授信额度 提供担保的实施公告。公告称，截至本公告披露日，公司对控股子公司提供的担保总额度为3.56亿元 （含本次），占公司2024年经审计净资产约24.35亿元的14.62%，截至2025年9月30日，公司对控股子公 司提供的担保余额为1.27亿元。 2024年1至12月份，健民集团的营业收入构成为：医药工业占比49.83%，医药商业占比49.56%，其他业 务占比0.6%。 （记者 王可然） ...

证券代码：600976 证券简称：健民集团 公告编号：2025-034 健民药业集团股份有限公司 关于对子公司银行授信额度提供担保的实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 特别风险提示：公司本次担保的担保对象维生公司的资产负债率超过 70%， 敬请广大投资者注意担保风险。 为支持子公司业务发展，公司将为全资子公司武汉健民药业集团维生药品有 限责任公司（以下简称：维生公司）向中信银行股份有限公司武汉分行申请的综 合授信敞口额度提供连带责任保证。现将有关情况公告如下： 重要内容提示： 被担保人为全资子公司武汉健民药业集团维生药品有限责任公司（以下简 称：维生公司）； 公司本次为维生公司提供的担保金额为 5,000 万元，截至本公告披露日公 司已实际为维生公司提供的担保余额为 0 元； 一、担保情况概述 （一）担保情况简介 被担保人：武汉健民药业集团维生药品有限责任公司 债权人：中信银行股份有限公司武汉分行 担保金额：5,000 万元 担保方式：连带责任保证 担保期限：一年 担保情况：公司为维生公司向中信银行 ...

Group 1 - The core viewpoint of the article highlights the strategic partnerships formed by KJ Supply Chain Co., Ltd. with four major brands across different industries to enhance digital transformation and intelligent upgrades in supply chain management [2][3]. - KJ Supply Chain will provide customized smart supply chain solutions based on the specific characteristics and needs of each industry partner [2][3]. - The collaboration with Lenovo focuses on local storage and rapid allocation of goods, leveraging KJ's extensive warehousing network of over 160 locations [2][4]. Group 2 - The partnership with Jianmin Pharmaceutical aims to optimize supply chain management, enhance operational efficiency, and reduce delivery times and damage rates [3][4]. - KJ Supply Chain will offer one-stop operational services for e-commerce channels in collaboration with Zhenyan Biotechnology, utilizing major platforms like Tmall, JD, and Amazon [3][4]. - The cooperation with Heidi Garden will explore innovative paths in smart agriculture, establishing a standardized operational system across the entire supply chain from procurement to delivery [3][4]. Group 3 - KJ Supply Chain has a strong foundation in the smart supply chain sector, with a peak order processing capacity of 5 million orders per day and coverage in approximately 300 cities nationwide [4]. - The company has also established overseas warehouse networks in several Southeast Asian countries, indicating its capability in both domestic and cross-border logistics [4]. - Future plans include continuing to focus on customer needs and leveraging industry experience and technological innovation to deepen the application of smart supply chains across various sectors [4].